Compare ALCO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | PRQR |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 262.5M |
| IPO Year | 1994 | 2014 |
| Metric | ALCO | PRQR |
|---|---|---|
| Price | $38.27 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $45.00 | $7.78 |
| AVG Volume (30 Days) | 18.5K | ★ 720.9K |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.32 | $1.33 |
| 52 Week High | $45.01 | $3.10 |
| Indicator | ALCO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 27.72 |
| Support Level | $37.46 | $1.37 |
| Resistance Level | $42.05 | $1.99 |
| Average True Range (ATR) | 0.62 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 12.57 | 17.24 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.